Press Releases

Date	Title
October 21, 2020	Shattuck Labs to Present at TIGIT Therapies Digital Summit 2020
October 14, 2020	Shattuck Labs Announces Closing of Upsized Initial Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
October 8, 2020	Shattuck Labs Announces Pricing of Upsized Initial Public Offering
September 1, 2020	Shattuck Labs to Present at PEGS Summit 2020
August 31, 2020	Shattuck Labs Announces Initiation of Phase 1 Clinical Trial of SL-172154 (SIRPα-Fc-CD40L) for the Treatment of Ovarian Cancer
July 21, 2020	Shattuck Labs Appoints Helen M. Boudreau to Board of Directors
June 15, 2020	Shattuck Labs Announces Closing of $118 Million Series B Financing
February 25, 2020	Shattuck Labs to Present at 40th Annual Cowen Health Care Conference
February 18, 2020	Shattuck Labs Promotes Dr. Taylor Schreiber to Chief Executive Officer
February 4, 2020	Taylor Schreiber to speak at the 2020 PEGS: The Essential Protein Engineering & Cell Therapy Summit, May 4-8, Boston, MA

Investors